Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Acute mycophenolate overdose: case series and systematic literature analysis.

Ceschi A, Gregoriano C, Rauber-Lüthy C, Kupferschmidt H, Banner NR, Krähenbühl S, Taegtmeyer AB.

Expert Opin Drug Saf. 2014 May;13(5):525-34. doi: 10.1517/14740338.2014.903032. Epub 2014 Mar 21. Review.

PMID:
24655210
2.

Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.

Budde K, Glander P, Krämer BK, Fischer W, Hoffmann U, Bauer S, Grohmann J, Neumayer HH, Arns W.

Transplantation. 2007 Feb 27;83(4):417-24.

PMID:
17318074
3.

Do we need to worry about mycophenolate overdose?

Filler G, Ferrand A.

Expert Opin Drug Saf. 2014 May;13(5):521-4. doi: 10.1517/14740338.2014.905540. Epub 2014 Apr 1.

PMID:
24684200
4.

Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium.

Ortega F, Sánchez-Fructuoso A, Cruzado JM, Gómez-Alamillo JC, Alarcón A, Pallardó L, Morales JM, Oliver J, Guinea G; MYVIDA Study Group.

Transplantation. 2011 Aug 27;92(4):426-32. doi: 10.1097/TP.0b013e31822527ca.

PMID:
21760569
5.

Acute thiopurine overdose: analysis of reports to a National Poison Centre 1995-2013.

Gregoriano C, Ceschi A, Rauber-Lüthy C, Kupferschmidt H, Banner NR, Krähenbühl S, Taegtmeyer AB.

PLoS One. 2014 Jan 29;9(1):e86390. doi: 10.1371/journal.pone.0086390. eCollection 2014.

6.

Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients.

de Winter BC, van Gelder T, Glander P, Cattaneo D, Tedesco-Silva H, Neumann I, Hilbrands L, van Hest RM, Pescovitz MD, Budde K, Mathot RA.

Clin Pharmacokinet. 2008;47(12):827-38. doi: 10.2165/0003088-200847120-00007.

PMID:
19026038
7.

Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil.

Arns W, Breuer S, Choudhury S, Taccard G, Lee J, Binder V, Roettele J, Schmouder R.

Clin Transplant. 2005 Apr;19(2):199-206.

PMID:
15740555
8.

Comparing outcomes associated with dose manipulations of enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients.

Cooper M, Deering KL, Slakey DP, Harshaw Q, Arcona S, McCann EL, Rasetto FA, Florman SS.

Transplantation. 2009 Aug 27;88(4):514-20. doi: 10.1097/TP.0b013e3181b0e65e.

PMID:
19696634
9.

Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil.

Sánchez Fructuoso A, Calvo N, Moreno MA, Giorgi M, Conesa J, Barrientos A.

Transplant Proc. 2007 Sep;39(7):2194-6.

PMID:
17889135
10.
11.

Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients.

Massari P, Duro-Garcia V, Girón F, Hernández E, Juárez F, Castro C, Toledo M; myPROMS LatAm Study Group.

Transplant Proc. 2005 Mar;37(2):916-9.

PMID:
15848574
12.

EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects.

Sabbatini M, Capone D, Gallo R, Pisani A, Polichetti G, Tarantino G, Gentile A, Rotaia E, Federico S.

Fundam Clin Pharmacol. 2009 Oct;23(5):617-24. doi: 10.1111/j.1472-8206.2009.00711.x. Epub 2009 Jul 28.

PMID:
19656208
13.

Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus.

Djabarouti S, Duffau P, Lazaro E, Chapouly C, Greib C, Viallard JF, Pellegrin JL, Saux MC, Breilh D.

Expert Opin Pharmacother. 2010 Apr;11(5):689-99. doi: 10.1517/14656561003592144.

PMID:
20210680
14.

Improved gastrointestinal symptoms and quality of life after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients receiving tacrolimus.

Hwang HS, Hyoung BJ, Kim S, Oh HY, Kim YS, Kim JK, Kim YH, Kim YL, Kim CD, Shin GT, Yang CW.

J Korean Med Sci. 2010 Dec;25(12):1759-65. doi: 10.3346/jkms.2010.25.12.1759. Epub 2010 Nov 24.

15.

Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.

Budde K, Glander P, Diekmann F, Dragun D, Waiser J, Fritsche L, Neumayer HH.

Transplant Proc. 2004 Mar;36(2 Suppl):524S-527S.

PMID:
15041401
16.

Randomized crossover study to assess the inter- and intrasubject variability of morning mycophenolic acid concentrations from enteric-coated mycophenolate sodium and mycophenolate mofetil in stable renal transplant recipients.

Tedesco-Silva H, Felipe CR, Park SI, Pinheiro-Machado PG, Garcia R, Slade A, Schmouder R, Medina-Pestana JO.

Clin Transplant. 2010 Jul-Aug;24(4):E116-23. doi: 10.1111/j.1399-0012.2009.01183.x.

PMID:
20047618
17.
18.

Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients.

Sollinger HW, Sundberg AK, Leverson G, Voss BJ, Pirsch JD.

Transplantation. 2010 Feb 27;89(4):446-51. doi: 10.1097/TP.0b013e3181ca860d.

PMID:
20177347
19.

Overdose of mycophenolate mofetil managed in a secondary care hospital in South India.

Alex R, Mathew M, Arul S, Kundavaram A.

Indian J Pharmacol. 2014 May-Jun;46(3):337-8. doi: 10.4103/0253-7613.132191.

20.

Superior efficacy of enteric-coated mycophenolate vs mycophenolate mofetil in de novo transplant recipients: pooled analysis.

Salvadori M, Bertoni E, Budde K, Holzer H, Civati G, Lien B, Arns W.

Transplant Proc. 2010 May;42(4):1325-8. doi: 10.1016/j.transproceed.2010.03.044.

PMID:
20534293

Supplemental Content

Support Center